摘要
目的:评价肝癌患者化疗前后血清可溶性Apo-1/Fas(sApo-1/Fas)水平变化的临床意义。方法:采用酶联免疫吸附试验法(ELISA)检测30例正常人及58例肝癌患者化疗前后血清sApo-1/Fas水平,并作对比分析。结果:肝癌患者血清sApo-1/Fas水平明显高于正常对照组(P<0.01),Ⅲ期肝癌血清sApo-1/Fas水平明显高于Ⅱ期(P<0.01),化疗后有效(完全缓解和部分缓解)患者血清sApo-1/Fas水平明显低于化疗前者(P<0.01),血清sApo-1/Fas水平与肝癌患者性别、年龄均无相关。结论:血清sApo-1/Fas可能参与调控肝癌的发生、发展过程,可作为化疗疗效和判断预后观察指标。
Objective:To evaluate the prognostic significance of serum soluble Apo-1/Fas changes in hepatocellular carcinoma patients(HCC)pre-and post-chemotherapeutically.Methods:Enzyme linked immunosorbent assay(ELISA)was used to detect the sApo-1/Fas level in58cas-es of HCC pre-and post-chemotherapeutically and30normal individuals as control.Results:The level of sApo-1/Fas elevated in HCC group as compared with control group(P<0.01).The level of sApo-1/Fas in stageⅢwas higher than that of stageⅡ(P<0.01).The sApo-1/Fas level re-duced markedly in complete remission or partial remission patients(P<0.01),but it was not sig-nificantly correlated with the sex and age of patients.Conclusion:sApo-1/Fas may play an im-portant role in development and growth of HCC.It is suggested that monitoring the sApo-1/Fas level changes has clinical and prognostic significance in HCC patients and further prospective study is needed.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2002年第4期234-236,240,共4页
Chinese Journal of Clinical Oncology
基金
广东省医学科研基金资助(B1999138)
